AbbVie Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-81.9% vs price
Base Case (Median)
-66.4% vs price
Bull Case (75th pct.)
-60.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-105.55 | -142.1% | High (40%) |
| PE Comparable | $45.40 | -81.9% | Medium (25%) |
| EV/EBITDA | $99.02 | -60.5% | Medium (20%) |
| EV/FCF | $234.39 | -6.6% | Medium (20%) |
| Earnings Power Value | $84.34 | -66.4% | Medium (50%) |
Based on 5 out of 8 methods, ABBV appears overvalued at the current price of $250.88. The base case fair value of $84.34 implies 66.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.